Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 5/20 | 0.44 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.37 |
| ▸ | BAD | Q92934 | 1/20 | 0.37 |
| ▸ | CD44 | P16070 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19678831 | 0.95 | PNMT (0.46) | PNMTPRCPHTR2CHTR2BCD44 | |
| SCHEMBL12903032 | 0.88 | PNMT (0.56) | PNMTPRCPHTR2CCD44 | |
| SCHEMBL24604599 | 0.81 | BCL2L1 (0.50) | BCL2L1BAD | |
| SCHEMBL16559767 | 0.79 | CA2 (0.40) | PNMTPRCPCD44 | |
| SCHEMBL11337766 | 0.79 | PNMT (0.46) | PNMTPRCPHTR2CHTR2BCD44 | |
| SCHEMBL12903030 | 0.78 | CD44 (0.56) | PNMTPRCPHTR2CCD44 | |
| SCHEMBL19684557 | 0.78 | PNMT (0.47) | PNMTPRCPHTR2CHTR2BBCL2L1 | |
| SCHEMBL11771379 | 0.77 | BCL2L1 (0.45) | BCL2L1BAD | |
| SCHEMBL11947412 | 0.76 | HTR2C (0.48) | PNMTPRCPHTR2CHTR2BCD44 | |
| SCHEMBL19711056 | 0.75 | PNMT (0.47) | PNMTPRCPHTR2CHTR2BBCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10220037-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | PNMT 2003/4885PRCP 664/4885HTR2C 4759/4885 |
| US-10220037-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | DUT, NCL, TYMP | PNMT 2003/4885PRCP 664/4885HTR2C 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.